News | May 25, 2026
SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth
Revenue from operations climbed 13% to Rs. 886.87 crore
Revenue from operations climbed 13% to Rs. 886.87 crore
The company’s EBITDA margin remained resilient above 20%
The inspection concluded with one minor observation in Form 483
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025
The inspection concluded with zero Form 483 observations
This significant milestone enhances our global regulatory standing
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Subscribe To Our Newsletter & Stay Updated
